Skip to main content
. 2017 Jul 6;19(9):874–883. doi: 10.1111/jch.13009

Figure 1.

Figure 1

Study designs for the United States and European centers. (A) Azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) treatment arm in all regions. (B) Olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) treatment arm in the United States. (C) OLM/HCTZ treatment arm in Europe. HTN indicates hypertension